Tonix Pharmaceuticals publishes investor deck focused on TONMYA fibromyalgia launch and pipeline programs

PUBT·06/15/2026 18:31:16

Listen to the news

Tonix highlighted TONMYA’s U.S. commercial rollout for fibromyalgia, citing USD 3.7 million in 1Q’26 net sales.
Cash and cash equivalents of about USD 185.5 million at March 31, 2026; no debt; cash runway projected into early Q2’27.
Launch metrics through April 2026: more than 2,600 unique prescribers; about USD 5.1 million net sales from Nov. 17, 2025 to Mar. 31, 2026.
Pipeline focus includes TNX-4800 Lyme disease prevention study planned for 1H’27; TNX-1500 Phase 2 study planned for 2H’26.
Additional programs include TNX-2900 Phase 2 study planned for 1Q’27; TNX-102 SL Phase 2 work in major depressive disorder, acute stress disorder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on June 15, 2026, and is solely responsible for the information contained therein.

FAQ

Fee Schedule Open Account Deposit & Withdrawal Trading

Terms & Conditions

Client Agreement Privacy Policy Data Disclaimer Security Tips

About Webull

About us Webull Promotions Contact information Announcements

Contact Number :+852 3852 8500

Monday 7:00 AM - Saturday 9:00 AM (HKT)

Service Email :service@webull.hk

Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)

Business Cooperation :marketinghk@webull.hk

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.

Language

English